Understanding supplements.
How do I evaluate what you're actually buying — in the pancreas aisle?
The pancreatic-supplement market sells to fear — a gland whose diseases are terrifying and whose treatments are prescription-only. The shelf offers 'pancreas cleanses,' 'enzyme capsules' at tiny fractions of prescription doses, and 'blood-sugar balancers' aimed at diabetics. The honest shelf is narrow: a test-guided vitamin, the antioxidant-trial arm at its toxicity-respecting ceiling, and the metabolic cluster's omega-3. Evaluation here means knowing what a real enzyme dose looks like — and it looks like a prescription.
Capsules
D3 and selenium — standard delivery
Softgels
Omega-3 — with fat, EPA counted
Enteric-Coated (Rx)
PERT — the form IS the function
'Enzyme Blends' (OTC)
The dose problem — see below
D3 · Cholecalciferol
The skin-synthesis form, superior at raising and sustaining blood levels — the standard choice, taken with a fat-containing meal.
The Test Rule
The islet evidence belongs to deficiency correction — supplementing a replete patient adds nothing. The 25-OH vitamin D test converts hope into measurement.
Choosing the Right Form & Dose
Label literacy in the pancreas aisle has three specific jobs:
- D3 test-guided: 1000–2000 IU maintenance, deficiency correction above that with supervision, always with a fat-containing meal.
- Selenium ceiling arithmetic: 200 mcg/day TOTAL from all sources — the capsule, the Brazil nuts, the multivitamin. Add them before buying anything.
- Enzyme reality check: for actual insufficiency, the lipase-unit number on a prescription bottle is what works — an OTC blend's blend is a snack, not a treatment.
- The standing rule: acute symptoms (severe pain, jaundice, new lean diabetes) go to the hospital, never the shelf.
Red Flags to Watch For
The pancreatic market sells to fear of medicine's hardest diseases. Be highly cautious of products that:
- Promise to 'cleanse' or 'detox' the pancreas — the gland has no cleansing pathway, and its diseases are hospital diseases; the claim exploits fear.
- Market 'digestive enzymes' as insufficiency treatment — the dose-and-coating gap (above) makes the substitution a malnutrition risk.
- Sell 'blood-sugar balancing' proprietary blends — unregulated stacks aimed at diabetics, the most medication-sensitive audience on this site.
- Lack third-party verification (USP, NSF, ConsumerLab, IFOS) — with selenium toxicity and dose-sensitive agents in this category, label accuracy is safety.